Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States
Abstract
The anti-fibrotic medications nintedanib and pirfenidone were approved in the United States for use in patients with idiopathic pulmonary fibrosis several years ago. While there is a growing body of evidence surrounding their clinical effectiveness, these medications are quite expensive and no prior cost-effectiveness analysis has been performed in the United States.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 10, 2022
- Source ID
- 10.1186/s12890-021-01811-0
Entities
People
- Andrew H. Limper
- Bijan J. Borah
- James P. Moriarty
- Timothy M. Dempsey
- Viengneesee Thao